At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 153 enrolled
Drug / intervention
ABT-493 coformulated with ABT-530drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection and Human Immunodeficiency Virus-1 (HIV-1) Co-Infection (EXPEDITION-2)
In Brief
A Phase 3 clinical trial evaluating ABT-493 coformulated with ABT-530 for Hepatitis C Virus Infection and 3 related conditions. Completed, enrolled 153 participants.
Detailed Summary
The purpose of this study is to assess the efficacy and safety of ABT-493/ABT-530 in adults with chronic hepatitis C virus genotype 1-6 infection and human immunodeficiency virus-1 co-infection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C Virus Infection, Human Immunodeficiency Virus Infection, Chronic Hepatitis C, Compensated Cirrhosis and Non-cirrhotics
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 2016
Enrollment StartMay 2016
Primary CompletionMar 2017
Study CompletionJun 2017
TodayJul 2026
First PostedApr 14, 2016
Enrollment StartMay 17, 2016
Primary CompletionMar 15, 2017
Study CompletionJun 7, 2017
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 10.2 years ago
Interventions
ABT-493 coformulated with ABT-530drug
Tablet